Novan (NOVN) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Novan (NASDAQ:NOVN) from a strong sell rating to a sell rating in a research report report published on Friday morning.

A number of other equities analysts have also issued reports on the stock. Piper Jaffray Companies restated a buy rating on shares of Novan in a research report on Thursday, August 3rd. Zacks Investment Research upgraded shares of Novan from a sell rating to a hold rating in a research report on Wednesday, October 4th. Finally, Wedbush restated a neutral rating and set a $6.00 target price on shares of Novan in a research report on Monday, September 25th.

Shares of Novan (NASDAQ:NOVN) traded down $0.04 on Friday, hitting $4.82. 30,900 shares of the stock were exchanged, compared to its average volume of 220,701. Novan has a twelve month low of $3.52 and a twelve month high of $30.90.

An institutional investor recently bought a new position in Novan stock. Goldman Sachs Group Inc. acquired a new stake in Novan Inc. (NASDAQ:NOVN) during the second quarter, according to its most recent filing with the SEC. The firm acquired 25,972 shares of the company’s stock, valued at approximately $105,000. Goldman Sachs Group Inc. owned about 0.16% of Novan at the end of the most recent reporting period. Institutional investors own 5.84% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Novan (NOVN) Stock Rating Upgraded by ValuEngine” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/05/novan-novn-stock-rating-upgraded-by-valuengine.html.

Novan Company Profile

Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Novan Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply